Apellis Pharmaceuticals, Inc.
DelistedCIK 1492422fmd_15HFQXXZ5ZYZ3SR7E9YQ7D6QZ3Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Mar 31, 2026, 42 periods
Latest annual · FY2025
Millions- Total revenues
- 1,004
- Operating income
- 55
- Net income
- 22
- Free cash flow
- 45
Latest quarter · Q1 FY2026
Millions- Total revenues
- 268
- Operating income
- 26
- Net income
- 19
- Free cash flow
- (14)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +137.0%
- Revenue, 5 yearsFY2020 to FY2025
- +32.0%
- Net income, 5 yearsFY2020 to FY2025
- n/m
Apellis Pharmaceuticals, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $1 billion | $781.4 million | +28.5% | 10-K 2026-02-24 · proof |
| Operating income | $55.4 million | -$165 million | 10-K 2026-02-24 · proof | |
| Net income | $22.4 million | -$197.9 million | 10-K 2026-02-24 · proof | |
| Cash from operating activities | $45.3 million | -$87.9 million | 10-K 2026-02-24 · proof | |
| Free cash flow | $45 million | -$88.3 million | 10-K 2026-02-24 · proof | |
| Total assets | $1.1 billion | $885.1 million | +21.5% | 10-K 2026-02-24 · proof |
| Total liabilities | $705.1 million | $656.5 million | +7.4% | 10-K 2026-02-24 · proof |
| Cash and cash equivalents | $466.2 million | $411.3 million | +13.4% | 10-K 2026-02-24 · proof |
- What was Apellis Pharmaceuticals, Inc.'s revenue in fiscal 2025?
- Apellis Pharmaceuticals, Inc. reported revenue of $1 billion for fiscal 2025 (the year ended Dec 31, 2025), against $781.4 million the year before (+28.5%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was Apellis Pharmaceuticals, Inc.'s operating income in fiscal 2025?
- Apellis Pharmaceuticals, Inc. reported operating income of $55.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$165 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was Apellis Pharmaceuticals, Inc.'s net income in fiscal 2025?
- Apellis Pharmaceuticals, Inc. reported net income of $22.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$197.9 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was Apellis Pharmaceuticals, Inc.'s cash from operating activities in fiscal 2025?
- Apellis Pharmaceuticals, Inc. reported cash from operating activities of $45.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$87.9 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was Apellis Pharmaceuticals, Inc.'s free cash flow in fiscal 2025?
- Apellis Pharmaceuticals, Inc. reported free cash flow of $45 million for fiscal 2025 (the year ended Dec 31, 2025), against -$88.3 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are Apellis Pharmaceuticals, Inc.'s total assets?
- As of Dec 31, 2025, Apellis Pharmaceuticals, Inc. reported total assets of $1.1 billion, against $885.1 million a year earlier (+21.5%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are Apellis Pharmaceuticals, Inc.'s total liabilities?
- As of Dec 31, 2025, Apellis Pharmaceuticals, Inc. reported total liabilities of $705.1 million, against $656.5 million a year earlier (+7.4%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are Apellis Pharmaceuticals, Inc.'s cash and cash equivalents?
- As of Dec 31, 2025, Apellis Pharmaceuticals, Inc. reported cash and cash equivalents of $466.2 million, against $411.3 million a year earlier (+13.4%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1492422&period_type=annual&limit=5"Information only, not investment advice.